Business, energy, technology, markets and global industry news from Business News Today

fentanyl

PharmaDeviceNews fentanyl
Representative image of a clinician preparing an injectable treatment in an outpatient care setting, illustrating Braeburn’s latest BRIXADI data on long-acting buprenorphine, opioid withdrawal suppression, and treatment retention in opioid use disorder.
Pharma & Biotech

Braeburn’s BRIXADI evidence package raises new questions for injectable buprenorphine adoption

Braeburn’s new BRIXADI data shows retention and dosing signals in opioid use disorder. Find out what it means for treatment strategy.

Read More
Representative image: Indivior’s SUBLOCADE 300 mg dose is gaining attention for its potential to improve outcomes in high-frequency fentanyl users, signaling a shift in opioid use disorder treatment strategies.
Pharma & Biotech

Indivior’s SUBLOCADE shows stronger outcomes in high-frequency fentanyl users: What this changes for opioid use disorder treatment in 2026

Indivior's new data shows SUBLOCADE 300 mg may improve outcomes in fentanyl users with OUD. Find out what this means for future treatment.

Read More